CCM
AVDL

CAAS Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

CAAS Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,000
Closed -$91.6K – 689
2023
Q1 		$91.6K Buy
+10,000
New +$82.2K ﹤0.01% 627

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

CAAS Capital Management's AVDL Position: Q2 2023 in Review

CAAS Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2023, closing a stake of 10,000 shares — an estimated $91.6K sold.

CAAS Capital Management first reported a position in AVDL in Q1 2023 and held it in 1 quarter. The position peaked at $91.6K in Q1 2023. 101 funds tracked by Wall St. Rank hold AVDL as of Q2 2023.

  • CAAS Capital Management reported no remaining Avadel Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • CAAS Capital Management sold 10,000 Avadel Pharmaceuticals shares in Q2 2023, an estimated $91.6K.
  • CAAS Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • CAAS Capital Management's Avadel Pharmaceuticals position peaked at $91.6K in Q1 2023.
  • 101 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2023.

Based on CAAS Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.